BSECompany Update31 Jul 2026 · 31 Jul 2026, 03:04 pm

Please find enclosed details of Earning call Transcript held on 30th July 2026.

Piramal Pharma Ltd · 543635

✦ AI SummaryResults

Piramal Pharma Ltd has made available the transcript of its earnings call on unaudited financial results for the quarter ended 30th June, 2026, on its website.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Attachments (1)

📄

6e945788-94c4-4aff-8aea-0dd4f7ef5047.pdf

pdf

Download →
View document text
31st July, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Transcript of Conference Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026 Dear Sir / Madam, In continuation of our letter dated 20th July, 2026 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the Conference Call held on 30th July, 2026, on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2026, is available on the Company’s website at https://www.piramalpharma.com/financial-reports. Kindly take this on record. Thanking you, Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com